한국지질동맥경화학회 학술대회

Symposium 2, titled “Cutting-edge Nutritional Approach for Cardiometabolic Risk Strategies,” will highlight the latest research in nutritional science aimed at preventing and treating cardiovascular and metabolic diseases. Professor Jordi Merino Ribas (University of Copenhagen, Denmark) will examine the interplay between molecular and environmental factors in the new era of precision medicine, laying the foundation for personalized nutritional strategies. Professor Hyun Ju You (Seoul National University, Republic of Korea) will assess the relationship between the human microbiome and cardiometabolic health. Dr. Hyekyoung Sung (York University, USA) will then present in-depth insights into the nutritional regulation of iron metabolism in cardiometabolic diseases. These distinguished presentations will feature the efficacy of personalized nutritional interventions in guiding comprehensive prevention and management strategies for cardiovascular and metabolic disorders.

The rapid advancement of artificial intelligence (AI) is transforming precision diagnostics and risk stratification in atherosclerosis and cardiovascular diseases. In this symposium, leading experts will present the most recent studies leveraging AI for accurate diagnosis and risk assessment of cardiovascular conditions. Professor Paul Leeson from University of Oxford, UK, will provide insights from the PROTEUS randomized controlled trial (RCT), demonstrating how AI-assisted stress echocardiography can enhance the diagnosis of coronary atherosclerosis and cardiovascular risk prediction. Subsequently, Dr. Junmyung Kwon from Medical AI, Republic of Korea, will discuss the application of AI-enhanced electrocardiography technology for early detection of acute myocardial infarction and effective cardiovascular risk stratification. Lastly, Professor SungA Bae from Yonsei University, Republic of Korea, will present findings from the AI-Gatekeeper RCT trial, comparing artificial intelligence-based screening of coronary artery disease with usual clinical care, showcasing its clinical advantages and potential implications. This symposium provides an excellent opportunity to explore how integrating clinical medicine with AI technology is shaping the future of precision cardiovascular medicine.

This joint symposium, “Familial Hypercholesterolemia in the Era of Precision Medicine,” brings together experts from Korea, Japan, and Taiwan to explore cutting-edge strategies in FH care. The session will begin with an update on advances in FH management beyond statins, followed by a presentation on the role of genetic screening and cascade testing for early detection. A third lecture will address the question of cardiovascular risk in FH, focusing on how early intervention should be considered. The symposium will conclude with a panel discussion, providing an opportunity to share perspectives and experiences across the three countries, and to highlight the potential of precision medicine in shaping personalized management of FH.

In AAS-KSoLA Joint Symposium, we will learn about current insights and future directions on comprehensive strategies for the prevention of atherosclerosis. In the first lecture, Professor Andrew Murphy, an invited lecturer of the Australian Atherosclerosis Society, will present a lecture on emerging biomarkers and anti-inflammatory treatments related to the topics of atherosclerosis and inflammation. In the next lecture, we will learn about the role of digital health technology in managing atherosclerosis. In the last lecture, we prepared an opportunity to hear about the effects of lipid-lowering treatment on the progression of aortic aneurysms and clinical outcomes. This session will provide a comprehensive overview of the research achievements in the basic fields related to the progression of atherosclerosis and the digital management system, as well as the effects of lipid-lowering agents on the progression of aortic aneurysms, which are clinically significant diseases.

Although luminal narrowing has traditionally guided our understanding of intracranial atherosclerosis and captured clinicians’ attention, growing evidence reveals that its impact reaches well beyond narrowing alone. This session, “What Is Important beyond Stenosis in Intracranial Atherosclerosis,” explores three key dimensions-vascular tortuosity and plaque burden, vessel wall enhancement and inflammation, and blood viscosity’s role in cerebral flow and stroke risk. Professor Mi-Yeon Eun, who is a stroke neurologist and neuro-interventionist from Kyungbook National University Chilgok Hospital, Republic of Korea, will present the relation between intracranial vascular tortuosity and overall atherosclerosis burden. Professor Dong-Wan Kang, a stroke neurologist from Seoul National University Bundang Hospital, Republic of Korea, will present the clinical impact of vascular enhancement and inflammation detected from high resolution vessel wall MRI. Professor Ho Geol Woo, a stroke neurologist and neuro-interventionist from Kyung Hee University Hospital, Republic of Korea, will present how blood viscosity affect development and stability of intracranial atherosclerosis. Together, these insights push us toward a more holistic approach to diagnosis and management of intracranial atherosclerosis.

This session will explore ethnic-specific characteristics of dyslipidemia, with a focus on Asian populations, and discuss optimal lipid-lowering strategies tailored to diverse clinical needs. The first speaker, Professor Jaehoon Chung from Dongguk University, Republic of Korea, will focus on hypertriglyceridemia and low HDL-C commonly observed in Asian populations, introducing a novel approach to treatment prioritization. Next, Professor Chang Hee Jung from University of Ulsan, Republic of Korea, will discuss the need for combination lipid-lowering therapy in patients for whom statin monotherapy is insufficient, supported by recent clinical evidence. Finally, Professor Hoang Anh Tien from Hue University of Medicine and Pharmacy, Vietnam, will emphasize the importance of personalized treatment strategies that account for ethnic differences between Asian and Western populations, highlighting both regional guideline variations and shared principles. Join us for this session to gain practical insights into diverse lipid management strategies applicable to clinical practice.

This session, held as a joint symposium with the Canadian Society of Atherosclerosis, Thrombosis and Vascular Biology (CSATVB), will discuss how lifelong LDL cholesterol burden affects cardiovascular health and highlight the importance of timely, targeted prevention, while also extending the discussion to ApoB and non-HDL cholesterol as markers for early risk assessment. Professor Warren Lee (University of Toronto, Canada) will describe the mechanisms by which LDL particles cross the vascular endothelium and promote atherosclerosis, with a focus on endothelial transcytosis as a potential therapeutic target. Following this, Professor Aram Yang (Sungkyunkwan University, Republic of Korea) will address cardiovascular risk management in youth, discussing when and how to intervene for optimal long-term outcomes. The session will conclude with Professor Jae Hyoung Park (Korea University, Republic of Korea), who will examine the role of ApoB and non-HDL cholesterol in the early prevention of cardiovascular disease. Overall, this joint symposium integrates mechanistic insights with practical strategies to support lifelong cardiovascular risk reduction.

The KoSFoST–KSoLA Joint Symposium on the “Role of Medicinal Foods in Atherosclerosis and Cardiometabolic Disease” was co-organized by the Health Functional Foods Division of the Korean Society of Food Science and Technology (KoSFoST) and the Korean Society of Lipid and Atherosclerosis (KSoLA). Professor Hun-Jun Park (Catholic University of Korea, Republic of Korea) will discuss novel health functional products designed to prevent pathological remodeling after myocardial infarction. Professor Sung Keun Jung (Kyungpook National University, Republic of Korea) will highlight how ultrasonicated Lespedeza cuneata extract can prevent early atherosclerosis, underscoring the critical role of processing techniques. Finally, Dr. Jiyun Ahn (Korea Food Research Institute, Republic of Korea) will examine strategies for regulating mitochondrial metabolic reprogramming during aging and provide systematic insights for anti-aging interventions. Following these distinguished presentations, the session will proceed with in-depth discussions regarding the role and practical development of medicinal foods in managing atherosclerosis and cardiometabolic disease.

The importance of remnant cholesterol has been increasingly highlighted in atherosclerotic cardiovascular diseases and various other diseases. First, Prof. Alberto Zambon from the University of Padua, Italy, will present on the mechanisms by which remnant cholesterol contributes to atherosclerotic cardiovascular disease and its clinical significance. Next, Prof. Soo Yeon Jang from Korea University, Republic of Korea, will present the role of remnant cholesterol in chronic kidney disease, and Prof. Han Na Jung from Hallym University, Republic of Korea, will present on its role in dementia. Lastly, Prof. Meral Kayikcioglu from Ege University, Türkiye, will present the role of remnant cholesterol in women's cardiometabolic health. We hope this session will reaffirm the importance of remnant cholesterol and serve as an opportunity to broaden our knowledge.